-
EyePoint Pharmaceuticals Proposes Public Offering of Common Stock
Post on 3/27/19
-
Avant-garde Health and Titanium Healthcare Partner
Post on 3/27/19
-
Fresenius Medical Care North America Renews Partnership with National Kidney Foundation
Post on 3/27/19
-
Syndax Announces $26.2 Million Offering of Common Stock and Warrants
Post on 3/27/19
-
Juvenescence Capitalizes BYOMass With up to $6.5 Million
Post on 3/27/19
-
Biogen Should Reconsider Its Strategic Shift To Neuro-Degenerative Disorders
Post on 3/27/19
-
Biogen's Bad News for Everyone
Post on 3/27/19
-
Harvard Bioscience To Showcase Products at Experimental Biology 2019
Post on 3/26/19
-
Selecta Biosciences Announces New Employment Inducement Grant
Post on 3/26/19
-
TCR2 Therapeutics Announces Collaboration With Cell and Gene Therapy Catapult
Post on 3/26/19
-
Archway Health Announces Partnership With A-Rated Insurance Carrier
Post on 3/26/19
-
ReviveMed Receives Frost & Sullivan AI-Driven Next-Generation Metabolomics Technology Innovation Award
Post on 3/26/19
-
Celgene/Bristol-Myers Merger: The Arb Spread Continuum Offers Clues
Post on 3/26/19
-
Celgene's Shareholders, Not Bristol-Myers Squibb's, Should Reject The Deal
Post on 3/26/19
-
Biogen - Pipeline Setback Looks To Create An Opportunity
Post on 3/26/19
-
Akebia Therapeutics: Still A Buy Post-Merger
Post on 3/26/19
-
SilverCloud Health's Digital Mental Health Platform Selected for NIMH & Washington University Research Study
Post on 3/25/19
-
SEQENS North America Wins Big at 2019 Life Science Leader Magazine CMO Leadership Awards
Post on 3/25/19
-
Curis Sells Portion of Erivedge Royalties To Oberland Capital For Up To $135.7 Million
Post on 3/25/19
-
Bristol-Myers Squibb Board Sends Letter to Shareholders Regarding Merger With Celgene
Post on 3/25/19
-
2019’s Best & Worst States for Doctors – WalletHub Study
Post on 3/25/19
-
Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals
Post on 3/25/19
-
Is Biogen a Bad-News Buy Now?
Post on 3/25/19
-
2 Biotech Takeout Targets Perfect for Biogen
Post on 3/25/19
-
resTORbio Closes Public Offering of Common Stock
Post on 3/24/19